Massachusetts Financial Services CO Cytom X Therapeutics, Inc. Transaction History

Massachusetts Financial Services CO

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$2.67 - $4.68 $953,547 - $1.67 Million	-357,134 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$3.87 - $7.39 $120,689 - $230,464	-31,186 Reduced 8.03%	357,134 $1.55 Million
Q3 2021 Nov 10, 2021	BUY	$4.32 - $6.43 $400,040 - $595,430	92,602 Added 31.31%	388,320 $1.98 Million
Q2 2021 Aug 13, 2021	BUY	$6.33 - $9.91 $16,046 - $25,121	2,535 Added 0.86%	295,718 $1.87 Million
Q1 2021 May 13, 2021	BUY	$6.6 - $9.0 $245,638 - $334,962	37,218 Added 14.54%	293,183 $2.27 Million
Q4 2020 Feb 12, 2021	SELL	$6.47 - $7.9 $16,627 - $20,303	-2,570 Reduced 0.99%	255,965 $1.68 Million
Q3 2020 Nov 12, 2020	BUY	$6.55 - $8.83 $358,940 - $483,884	54,800 Added 26.9%	258,535 $1.72 Million
Q2 2020 Aug 11, 2020	SELL	$7.4 - $14.64 $38,406 - $75,981	-5,190 Reduced 2.48%	203,735 $1.7 Million
Q1 2020 May 14, 2020	BUY	$3.61 - $8.6 $119,379 - $284,393	33,069 Added 18.8%	208,925 $1.6 Million
Q4 2019 Feb 13, 2020	SELL	$5.17 - $8.91 $98,261 - $169,343	-19,006 Reduced 9.75%	175,856 $1.46 Million
Q3 2019 Nov 05, 2019	BUY	$7.38 - $12.25 $1.44 Million - $2.39 Million	194,862 New	194,862 $1.44 Million

50.7M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $69.9M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

Stay updated on Massachusetts Financial Services CO with notifications on news.